Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II lenvatinib + nivolumab + chemotherapy in first-line metastatic gastric cancer with malignant ascites
KCT0010902Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, nivolumab in gastric cancer (GC), sponsored by Boryung. Started Nov 2025; status: recruiting.
02
Drugs
lenvatinibnivolumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0010902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010902.